Amneal Pharmaceuticals (AMRX) Q4 FY25 earnings call: guidance and Q&A

Can you elaborate on the market response to CREXONT's Phase IV data and provide insights into revenue or market share targets for 2026?

Management highlighted positive market reception to the interim Phase IV data showing 3.13 hours of 'Good On' time, with 80% of IR patients converting to CREXONT. They expect to more than double CREXONT's market share in 2026, surpassing RYTARY's historical share, and will release more data in 2026 and 2027.

“Market share, we would double it in '26, more than double the revenue. And as we march towards the first goal is to reach 100,000 patients and second goalpost would be to reach 200,000 patients, reminding you, total is 700,000 patients on CD-LD treatment.”

asked by Chris Schott · answered by Chirag Patel

Please clarify the 2026 Health Care guidance, specifically the growth expectations for the government versus distribution channels and the gross margin outlook for the franchise.

Management explained the 2026 revenue decline is due to a strategic pivot away from low-profit distribution business and the loss of exclusivity for generic Entresto, which contributed $100 million in 2025. Despite the revenue dip, profitability is expected to remain flat year-over-year due to resource allocation to more profitable segments and operating expense management, with a resumption of growth in 2027.

“So that's what's going to drive the decline and what we like to call it almost like a reset level for 2026. But the bottom line is not going to be impacted because for a couple of reasons: a, there is other more profitable parts of the business. We will be allocating resources. We'll also be leaning on some of the operating expenses.”

asked by Chris Schott · answered by Anastasios Konidaris

Could you provide an update on the Pfizer GLP-1 obesity partnership, potential outcomes like a buyout, and plans for the new manufacturing facilities?

The collaboration with Pfizer continues, with facilities accelerating and C-level meetings ongoing. There are no current plans for a buyout, and Amneal retains marketing rights for 18 countries, including India and Southeast Asia. The new highly automated fill-and-finish and peptide manufacturing facilities are progressing well.

“So with Pfizer, our collaborations continues such as we had it with Metsera, both teams are working together. Facilities actually accelerated in manufacturing. And we -- several levels of C-level meetings have been already conducted with Pfizer. So we expect nothing much to change.”

asked by Matthew Dellatorre · answered by Chirag Patel

What are your latest thoughts on business development strategy, areas of interest, capacity, and the vertical integration of biosimilars?

Management stated that vertical integration in biosimilars is the primary capital allocation priority, given the market opportunity and regulatory streamlining. Post-2027, the focus will shift to building the specialty asset pipeline. The company also emphasized continued investment in organic R&D and CapEx.

“So as we've been saying it since last couple of years, time is now to do the vertical integration. Biosimilar opportunities are [ awesome ], regulatory is streamlined and we are very familiar with the market. So very excited that's where the capital allocation will go first.”

asked by Matthew Dellatorre · answered by Chirag Patel

What are your expectations for the generic Omnipaque opportunity in 2026, including barriers to competition and potential for additional strengths?

Management noted the complicated supply chain for Iohexol, expecting a ramp-up over time. They anticipate approval for missing strengths by the end of 2026, which will complete the Omnipaque portfolio. Due to manufacturing complexity and unique bottle requirements, they foresee limited competition, making it a meaningful revenue contributor from 2027 onwards.

“So on Iohexol your question on additional strength. So by end of the year, we will have approval for the missing trends. So by end of the year, we'll have the entire Omnipaque, all the strength. It's a very large opportunity for us.”

asked by David Amsellem · answered by Chintu Patel

What is your outlook for Biosimilar Xolair, particularly regarding limited competition and its market potential in 2027 and beyond?

Amneal is excited about Biosimilar Xolair, expecting to be among the first to market with Celltrion. They anticipate 65-70% of the market to go through private label channels, allowing for immediate market share gains rather than a slow ramp-up. Amneal's strong relationships with large buying groups position them well for this opportunity in the over $4 billion U.S. market.

“We expect 65% to 70% to go through the private label, which gives us immediate bump in the cells rather than ramp up over market share over 1, 2, 3 years. So exciting opportunity.”

asked by David Amsellem · answered by Chirag Patel

Can you quantify CREXONT's persistence and adherence versus RYTARY, discuss discontinuation rates, and the evolving gross-to-net at peak?

CREXONT's persistence and adherence are improving and surpassing RYTARY, with patients returning to therapy at a higher rate. The gross-to-net for CREXONT is typical for the category, around 40-45%. Management noted that pricing strategies for CREXONT have reduced prescription fill issues compared to RYTARY.

“CREXONT versus RYTARY. Obviously, CREXONT is performing much better as RYTARY, it took almost 10 years to get to 6% market share. First year, we have 3% market share, 23,000 patients on it. testimonials are amazing, and we've received letters and -- our office literally -- written letters from patient providers are -- physicians are so excited about the product as well.”

asked by Leszek Sulewski · answered by Chirag Patel